KLF4 reportedly acts as a tumor suppressor in gastric cancer 55, colorectal cancer 56, bladder cancer 57 and prostate cancer 58, where a significant decrease or loss in KLF4 expression is frequently observed. Here, KLF4 is linked to prostate carcinoma.